Polypid Ltd. (PYPD) — 6-K Filings

6-K Filings (36)

• PolyPid Initiates Phase 3 Trial for P-14 — Mar 31, 2026 Risk: medium
  On March 31, 2026, PolyPid Ltd. announced the initiation of a Phase 3 clinical trial for its lead product candidate, P-14, for the treatment of surgical site in
• PolyPid Ltd. Calls Extraordinary General Meeting for Feb 4, 2026 — Dec 31, 2025 Risk: low
  PolyPid Ltd. has filed a Form 6-K on December 31, 2025, to report its Notice of Meeting, Proxy Statement, and Proxy Card for an Extraordinary General Meeting of
• PolyPid Appoints Brooke Story as New Chairman — Dec 16, 2025 Risk: low
  PolyPid Ltd. announced on December 16, 2025, the appointment of Brooke Story as a director and chairman of its Board of Directors, effective December 11, 2025.
• 6-K Filing — Dec 3, 2025
• PolyPid Ltd. Boosts Share Offering Size to $15M — Nov 26, 2025 Risk: medium
  On November 26, 2025, PolyPid Ltd. announced an increase in the maximum aggregate offering price of its ordinary shares under its Sales Agreement with Oppenheim
• 6-K Filing — Nov 12, 2025
• PolyPid Clears Israeli Health Ministry GMP Inspection — Sep 16, 2025 Risk: medium
  PolyPid Ltd. announced on September 16, 2025, that it has successfully completed a Good Manufacturing Practice (GMP) inspection by the Israeli Ministry of Healt
• PolyPid Ltd. Appoints Nir Dror as Interim Chairman — Aug 13, 2025 Risk: low
  PolyPid Ltd. announced on August 11, 2025, that Nir Dror has been elected as the Interim Chairman of the Board. This follows the termination of Jacob Harel's se
• PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer — Aug 12, 2025 Risk: low
  PolyPid Ltd. announced on August 12, 2025, the appointment of Dr. Nurit Tweezer-Zaks as its new Chief Medical Officer. Dr. Tweezer-Zaks brings extensive experie
• PolyPid Launches GLP-1 Delivery Platform for Diabetes/Weight Loss — Jul 15, 2025 Risk: medium
  PolyPid Ltd. announced on July 15, 2025, the launch of a novel long-acting GLP-1 receptor agonist delivery platform. This platform is designed to target the sig
• PolyPid Ltd. Holds Shareholder Meeting, Re-elects Auditors — Jun 25, 2025 Risk: low
  On June 25, 2025, PolyPid Ltd. held its Annual and Extraordinary General Meeting of Shareholders. A key agenda item was the re-election of Kost Forer Gabbay & K
• PolyPid Ltd. Inducement Offer for January 2024 Warrants — Jun 17, 2025 Risk: medium
  On June 16, 2025, PolyPid Ltd. entered into an inducement offer letter agreement with holders of its January 2024 Warrants. These warrants, totaling 2,190,121,
• PolyPid's D-PLEX 100 Hits Endpoints in Phase 3 SHIELD II Trial — Jun 9, 2025 Risk: medium
  PolyPid Ltd. announced positive topline results on June 9, 2025, from its Phase 3 SHIELD II trial for D-PLEX 100. The study demonstrated a significant reduction
• PolyPid Ltd. Boosts Share Option Plan by 1.2M Shares — May 30, 2025 Risk: low
  On May 12, 2025, PolyPid Ltd. (the "Company")'s Board of Directors approved an increase of 1,200,000 ordinary shares to its Amended and Restated 2012 Share Opti
• PolyPid Ltd. Announces Shareholder Meeting for June 25 — May 21, 2025 Risk: low
  PolyPid Ltd. filed a Form 6-K on May 21, 2025, to announce its Annual and Extraordinary General Meeting of Shareholders. The meeting is scheduled for June 25, 2
• PolyPid Ltd. Reports Q1 2025 Financials and Corporate Update — May 14, 2025 Risk: medium
  PolyPid Ltd. reported its first quarter 2025 financial results on May 14, 2025. The company provided a corporate update, highlighting recent developments. Speci
• PolyPid Completes Enrollment in Phase 3 D-PLEX 100 Surgical Infection Trial — Mar 11, 2025 Risk: medium
  PolyPid Ltd. announced on March 11, 2025, the successful completion of patient enrollment for its Phase 3 SHIELD II trial. This trial is evaluating D-PLEX 100 f
• PolyPid Ltd. Appoints New Director — Feb 12, 2025 Risk: low
  PolyPid Ltd. announced on February 12, 2025, the appointment of Yitzchak Jacobovitz to its Board of Directors, effective February 10, 2025. Mr. Jacobovitz, 49,
• PolyPid Faces Nasdaq Delisting Over Equity Shortfall — Jan 17, 2025 Risk: medium
  PolyPid Ltd. received a non-compliance notification from Nasdaq on November 25, 2024, for failing to meet the minimum $2.5 million stockholders' equity requirem
• PolyPid Ltd. Secures Private Placement Funding — Dec 26, 2024 Risk: medium
  On December 23, 2024, PolyPid Ltd. announced a private placement financing led by existing institutional shareholders. The company will issue 4,493,830 ordinary
• PolyPid & ImmunoGenesis Partner for Cancer Immunotherapy — Dec 11, 2024 Risk: medium
  PolyPid Ltd. announced on December 11, 2024, a research and development collaboration with ImmunoGenesis. This partnership will leverage PolyPid's PLEX technolo
• PolyPid Gets Nasdaq Delisting Warning for Equity — Nov 29, 2024 Risk: high
  PolyPid Ltd. announced on November 29, 2024, that it received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirem
• PolyPid Ltd. Reports Q3 2024 Financials and Corporate Update — Nov 13, 2024 Risk: low
  PolyPid Ltd. announced its third quarter 2024 financial results and provided a corporate update on November 13, 2024. The company reported financial results for
• PolyPid Ltd. to Sell Up to $8.25M in Shares — Nov 8, 2024 Risk: medium
  On November 8, 2024, PolyPid Ltd. entered into a Sales Agreement with Oppenheimer & Co. Inc. as the Sales Agent. Through this agreement, PolyPid can offer and s
• PolyPid Enrolls Last Patient in SHIELD II Phase 3 Trial — Oct 1, 2024 Risk: medium
  PolyPid Ltd. announced on October 1, 2024, that the last patient has been enrolled for the planned unblinded interim analysis of their SHIELD II Phase 3 trial.
• PolyPid Ltd. Reports Q2 2024 Financials and Corporate Update — Aug 14, 2024 Risk: medium
  PolyPid Ltd. announced its second quarter 2024 financial results on August 14, 2024. The company provided a corporate update, highlighting recent developments.
• PolyPid Ltd. Raises $3.8M in Private Placement — Aug 2, 2024 Risk: medium
  On August 1, 2024, PolyPid Ltd. entered into a securities purchase agreement for a private placement financing. The agreement involves the sale of 2,235,457 ord
• PolyPid Terminates Cantor Fitzgerald Sales Agreement — Jul 19, 2024 Risk: medium
  PolyPid Ltd. announced on July 19, 2024, that it terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. effective July 15, 2024.
• PolyPid Ltd. Holds Shareholder Meeting, Re-elects Accountants — Jul 2, 2024 Risk: low
  PolyPid Ltd. held its Annual and Extraordinary General Meeting of Shareholders on July 2, 2024. A key agenda item was the re-election of Kost Forer Gabbay & Kas
• PolyPid Ltd. Discusses SSI Unmet Need & SHIELD II Trial Update — Jun 18, 2024 Risk: medium
  PolyPid Ltd. hosted a Key Opinion Leader (KOL) call on June 18, 2024, to discuss the significant unmet medical need in preventing surgical site infections (SSIs
• PolyPid Ltd. Announces Shareholder Meeting for July 2 — May 28, 2024 Risk: low
  PolyPid Ltd. has filed a Form 6-K on May 28, 2024, to announce its Annual and Extraordinary General Meeting of Shareholders. The meeting is scheduled for Tuesda
• PolyPid Ltd. Boosts Share Option Pool by 2M Shares — May 17, 2024 Risk: low
  On May 6, 2024, PolyPid Ltd. announced an increase in the number of ordinary shares available under its Share Option Plan. The Board of Directors approved an ad
• PolyPid Ltd. Reports Q1 2024 Financials and Corporate Update — May 8, 2024 Risk: medium
  PolyPid Ltd. reported its first quarter 2024 financial results on May 8, 2024. The company provided a corporate update, highlighting recent developments. Specif
• PolyPid Enrolls 200th Patient in SHIELD II Phase 3 Trial — Apr 30, 2024 Risk: medium
  PolyPid Ltd. announced on April 30, 2024, that it has enrolled the 200th patient in its SHIELD II Phase 3 clinical trial. This trial is evaluating D-PLEX 100 fo
• PolyPid Hits 100-Patient Milestone in SHIELD II Phase 3 Trial — Feb 14, 2024 Risk: medium
  PolyPid Ltd. announced on February 12, 2024, the enrollment of the 100th patient in its ongoing SHIELD II Phase 3 clinical trial. This significant milestone was
• PolyPid Raises $16.2M in Private Placement for SHIELD II Trial — Jan 5, 2024
  PolyPid Ltd. secured $16.2 million in gross proceeds from a private placement financing on January 4, 2024, by selling 3,371,312 ordinary shares at $4.81 per sh

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX